Ortho Clinical Diagnostics Announces Launch of New ISXM Capabilities
RARITAN, N.J., Sept. 27, 2021 /PRNewswire/ -- Ortho Clinical Diagnostics (NASDAQ: OCDX), one of the world's largest pure-play in vitro diagnostics (IVD) companies, today announced the availability of Immediate Spin Crossmatch (ISXM) on the company's ORTHO VISION® and ORTHO VISION® MAX Analyzers to aid in detecting incompatibility between donors and recipients in blood transfusions.
- RARITAN, N.J., Sept. 27, 2021 /PRNewswire/ -- Ortho Clinical Diagnostics (NASDAQ: OCDX), one of the world's largest pure-play in vitro diagnostics (IVD) companies, today announced the availability of Immediate Spin Crossmatch (ISXM) on the company's ORTHO VISION and ORTHO VISION MAX Analyzers to aid in detecting incompatibility between donors and recipients in blood transfusions.
- When a full crossmatch is performed, it is required to also complete an ISXM test.
- Ortho Clinical Diagnostics is powered by Ortho Care Service and Support, a global, award-winning, holistic service and support program designed to empower laboratorians to take full advantage of Ortho's solutions and consistently deliver the highest quality care.
- Ortho Clinical Diagnostics (Nasdaq: OCDX) is one of the world's largest pure-play in vitro diagnostics (IVD) companies dedicated to transforming patient care.